– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement – – Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes – – Favorable safety profile with no treatment-related serious...
Hence then, the article about halia therapeutics announces positive phase 2a data for ofirnoflast in lower risk mds at ash 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025 )
Also on site :
- Blessing Muzarabani ditches PSL team, joins KKR for IPL 2026
- Metal Logic Purchases Pilbara Site to Deploy Grade-Agnostic, Scalable Modular Clean Steel Smelter
- Games of the Future 2026 (Spiele der Zukunft 2026): Termine und Disziplinen für Astana bestätigt